Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

NCT03312283 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Age-related Macular Degeneration

Interventions

DRUG: lucentis
DRUG: QL1205

Sponsor

Qilu Pharmaceutical Co., Ltd.